Finnbarr D. Murphy

Finnbarr Murphy is a partner in Goodwin’s Life Sciences group. His practice is focused on the representation of issuers and underwriters in public and private securities offerings and he advises on corporate governance and SEC reporting and disclosure obligations. Mr. Murphy has experience with a wide variety of capital markets transactions involving US and non-US issuers, including initial public offerings (IPOs) and other equity offerings, convertible offerings, and investment-grade and high-yield debt financings. 

Mr. Murphy also counsels clients on liability management transactions (including tender offers, exchange offers, and consent solicitations), exchange listings (NYSE/Nasdaq), and mergers and acquisitions, including spinoffs, joint ventures, and cross-border transactions. He works with clients across numerous industries, including life sciences, technology, shipping, financial services, retail, media and telecommunications.

Mr. Murphy’s representative experience includes:

• A leading royalty acquisition company in connection with its $650 million Rule 144A offering of high yield notes*
• An oncology company in multiple at-the-market offerings, PIPEs, and underwritten public offerings*
• A gene therapy company in its underwritten public offering of ordinary shares*
• A global biopharmaceutical company in its $150 million equity investment in a clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics in conjunction with a strategic collaboration agreement*
• A biopharmaceutical company in its underwritten public offering and equity restructuring agreement with Elliott Management*
• A global inter-dealer broker in its underwritten public offering of common stock*
• A leading Italian telecommunications company in more than $10 billion of registered senior notes offerings*
• A global learning company in more than $1 billion of Rule 144A senior notes offerings*
• A leading provider of information solutions in its $600 million Rule 144A offering of convertible senior notes, and subsequent consent solicitations*
• A financial services company, as issuer, in its $750 million registered public offering of senior notes*
• Multinational investment banks as counsel to the underwriters in the IPOs of some of the world’s leading international shipping companies with an aggregate value of more than $2 billion, and in follow-on common stock and preferred stock offerings by such companies and others in excess of $3 billion*
• One of the largest independent owners of containerships in connection with its IPO and NYSE listing and subsequent public offerings and private placements of common stock*
• A shipping transportation company in connection with its IPO and Nasdaq listing and multiple registered follow-on offerings of common stock*
• One of the largest independent transporters of energy in the world in multiple common and preferred stock offerings*
• An integrated logistics company in its sale of $1 billion of Total SA ordinary shares*
• The underwriters of a leading provider of seaborne drybulk transportation services’ public offering of common stock*
• One of the largest independent owners of containerships in connection with its $300 million Rule 144A offering of high yield notes*
• The underwriters of a Greek dry bulk shipping company’s $700 million registered convertible senior note offerings and related share lending facilities*
• The underwriters of a high-yield notes offering by an international owner, operator, and manager of liquefied natural gas (LNG) carriers*
• A financial services company, as issuer, in its $750 million registered public offering of senior notes*
• The world’s largest producer of medicine and vaccinations for pets and livestock on securities law aspects of its acquisition of a clinical-stage biopharmaceutical company focused on the therapeutic market for companion animals via an Irish scheme of arrangement*
• A biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases, on securities law aspects of its sale to a global pharmaceutical company specializing in neurological diseases for cash and CVRs potentially representing more than $650 million*
• An investment fund in connection with the $150 million acquisition of the tanker fleet of a Nasdaq-listed company*
• A multinational investment bank and financial services company on securities law aspects of its $10 billion merger of equals*
• A global financial services company in connection with its $1 billion acquisition of an interdealer brokerage business*

*Denotes experience prior to joining Goodwin.

Before joining Goodwin, Mr. Murphy was a partner at Morgan, Lewis & Bockius LLP.

Mr. Murphy is a member of the New York City Bar Association, the American Bar Association, and the Association of the Bar of the City of New York Committee on Securities Regulation.

Mr. Murphy was named a Notable Practitioner by IFLR1000 in the United States from 2018 through 2021. He was also selected as a Recommended Lawyer by The Legal 500 United States from 2013 through 2016.

While attending law school, Mr. Murphy was a member of The Tax Lawyer.